We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Real-Time PCR Detects Drug Resistant Tubercle Bacillus

By LabMedica International staff writers
Posted on 03 Aug 2010
A new diagnostic test identifies drug resistance genes of Mycobacterium tuberculosis (TB) in various human biological materials

The real-time polymerase chain reaction (RT-PCR) test can simultaneously detect TB and the mutations of drug resistant TB genes in sputum, aseptic and pleural fluid, blood, bone marrow aspiration, bronchial washing, fresh tissue, culture specimens (solid and liquid culture), urine and stool. More...
The test for multi-drug resistant TB (MDR-TB) is completed within four hours.

Healthcare workers will be able to determine quickly whether or not a patient is infected with a strain of TB that is resistant to first line drugs such as isoniazid (INH) and rifampin (Rif). The Anyplex MDR-TB is a real-time detection test of M. tuberculosis that quickly and comprehensively determines the levels of targets in a patient's various sample types, and identifies mutations of drug resistant genes, which will aid physicians to make the correct diagnostic choices.

The Anyplex MDR-TB test is manufactured by Seegene (Rockville, MD, USA). The test can detect the mutations of drug resistant genes to Rif (rpoB: D516V/Y, H526D/Y, S531L) and INH (katG: S315T (2 cases); inhA promoter: -15(C/T)). The unprecedented speed and accuracy of the Anyplex MDR-TB Tests will enable doctors and clinicians to provide quickly an appropriate treatment to prevent the spread of MDR-TB.

Current TB test methods based on culture and microscopy are hindered by speed, low sensitivity, and low specificity. Furthermore, none of these approaches are able to identify rapidly and efficiently a patient's resistance to the major drugs for treating TB. Even if sequencing and Line Probe Assay are available to test drug resistance, the procedures are quite complicated and time-consuming.

The World Health Organization (WHO; Geneva, Switzerland), reported that TB strains that are resistant to all major anti-TB drugs have been documented in every country by the nongovernmental organization recent survey. A particularly dangerous form of drug-resistant TB is MDR-TB, caused by TB bacilli resistant to the most powerful anti-TB drugs. The rate for successful MDR-TB treatment is extremely low and the progress of the disease is faster than normal TB, resulting in 40% - 50% of mortality rate.

Jong-Yoon Chun, CEO of Seegene, said, "Because MDR-TB is difficult to treat, preventing its spread throughout the population is essential. The Anyplex MDR-TB Test is a powerful new tool that healthcare workers can use to rapidly determine such infections, which will both help stop it from spreading and allow health care professionals to set a course of alternative medications for infected patients."

Related Links:
Seegene
WHO


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.